Patent applications published 24 March 2010

Published: 6-Apr-2010


  • Therapeutic compounds
    University of Florida Research Foundation 2164364*

  • Oxyimino compounds and the use thereof
    Shionogi & Co 2164325*

  • Amide compounds and the use thereof
    Euro-Celtique; Shionogi & Co 2164326*

  • Radiolabelled fluorobenzamide analogues, their synthesis and use in diagnostic imaging
    Washington University 2164327*

  • Therapeutic pyrazoloquinoline urea derivatives
    Helicon Therapeutics 2164328*

  • Tissue non-specific alkaline phosphatase inhibitors and uses thereof for treating vascular calcification
    The Burnham Institute for Medical Research 2164329*

  • SERCA2 therapeutic compsns and methods of use
    Celladon 2164330*

  • Boron-containing small molecules
    Anacor Pharmaceuticals 2164331*

  • Stable non-aqueous pharmaceutical compsns
    Novo Nordisk 2164459*

  • Pharmaceutical formulation for the production of rapidly disintegrating tablets
    BASF 2164460*

  • Pharmaceutical formulation for the production of chewable tablets and lozenges
    BASF 2164461*

  • Pharmaceutical formulation for the production of rapidly-disintegrating tablets
    BASF 2164462*

  • Concentrate esmolol
    Baxter International 2164463*

  • Multidose concentrate esmolol with benzyl alcohol
    Baxter International 2164464*

  • Self-emulsifying formulation of tipranavir for oral administration
    Boehringer Ingelheim International 2164465*

  • Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier
    Novo Nordisk 2164466*

  • Slow release pharmaceutical compsn made of microparticles
    Debio Recherche Pharmaceutique 2164467*

  • Method for the production of a form of administration of a medicament
    Grünenthal 2164468*

  • Stable formulation of amorphous perindopril salts, a process for the preparation thereof on industrial scale and use thereof in the treatment of hypertension
    Silverstone Pharma 2164469*

  • Pharmaceutical compsn comprising desloratadine
    Ratiopharm 2164470*

  • Methods for improving physical function in fibromyalgia
    Cypress Bioscience 2164471*

  • Pharmaceutical compsn comprising a substrate and a coating containing an active ingredient and polyvinylalcohol
    Schering-Plough Healthcare Products 2164472*

  • An extended release compsn comprising a somatostatin derivative in microparticles
    Novartis 2164473*

  • Water dispersible polymer compsns
    Dow Global Technologies 2164474*

  • Therapeutic stable nanoparticles
    Northeastern University 2164475*

  • Topical compsn for treating pain
    Xvasive 2164476*

  • Pharmaceutical compsn having a trihydroxy-chromene derivative
    Analyticon Discovery 2164477*

  • PDZ domain modulators
    University of Copenhagen; NeuroSearch 2164478*

  • New sigma-receptor ligands with anti-apoptotic and/or pro-apoptotic properties over cellular biochemical mechanisms, with neuroprotective, anti-cancer, anti-metastatic and anti-(chronic) inflammatory action
    Vamvakides, Alexandre 2164479*

  • Mutual prodrugs and methods to treat cancer
    University of Maryland 2164480*

  • Medicament comprising an active substance combination containing pantothenic acid or the derivatives thereof for the treatment of allergy symptoms
    Bayer Consumer Care 2164481*

  • Combination comprising pyrrolidone-5-carboxylic acid and at least one compound from citrulline, arginine and asparagine, and use thereof in the treatment of atopic dermatitis
    Galderma Research & Development 2164482*

  • Transglutiminase inhibitor comprising chlorogenic acid and a method for producing thereof
    National Cancer Center 2164483*

  • Use of nitric oxide-releasing statins in the treatment of pulmonary arterial hypertension
    Nicox 2164484*

  • Combination of checkpoint kinase (CHK) and telaniectasia mutated (ATM) inhibitors for the treatment of cancer
    AstraZeneca 2164485*

  • Use of 4-phenyl-imidazole-2-thiones as tyrosinase inhibitors for preparing pharmaceutical or cosmetic compsns for treating or preventing pigment disorders
    Galderma Research & Development 2164486*

  • AMPA receptor antagonists and zonisamide for neuropathic pain
    Eisai R&D Management 2164487*

  • AMPA receptor antagonists and aldose reductase inhibitors for neuropathic pain
    Eisai R&D Management 2164488*

  • Combination of AMPA receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain
    Eisai R&D Management 2164489*

  • Pyrazoloyl derivatives with analgesic activity and therefore useful in the treatment of prophylaxis of pain
    AstraZeneca 2164490*

  • Piperidine-4-acetic acid derivatives and their uses
    Euroscreen 2164491*

  • (Thio)-carbamoyl-cyclohexane derivatives and method for treating schizophrenia
    Richter Gedeon Nyrt 2164492*

  • heteroaryl-substituted urea modulators of fatty acid amide hydrolase
    Janssen Pharmaceutica 2164493*

  • Methods of treatment
    GlaxoSmithKline LLC 2164494*

  • Use of derivatives of 3-oxo-2,3-dihydro-5H-thiazolo-3,2-A pyrimidine or of 3-oxo-2,3-dihydro-5H-selenazolo--3,2-A pyrimidine or of 3-oxo-1,2,3-trihydro-5H-imidazolo-1,2-A pyrimidine for the preparation of pharmaceutical compsns intended for the treatment of cancer
    Université Paris Descartes 2164495*

  • A drug delivery system for the prevention of cerebral vasospasm
    Macdonald, R; Leuthner, Brian 2164497*

You may also like